Clinical Trial Update: Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome) [Phase 3]

View source ↗

Summary

Phase 3 extension study of patidegib topical gel 2% for Basal cell nevus syndrome (Gorlin syndrome) has been terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Nevus Syndrome

Drugs mentioned

• Patidegib topical gel 2% (patidegib)

Snippet

Sponsor: Sol-Gel Technologies, Ltd. | Conditions: Basal Cell Nevus Syndrome | Phase 3 | Status: TERMINATED | Results posted: 2024-09-24